Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of LZM009 in recurrent or metastatic thymic carcinoma after failure of at least one line of chemotherapy
CTR20200784Phase 2Active
- Sponsor
- Lichen Biotech
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of lipustobart in thymic carcinoma (TC), sponsored by Lichen Biotech. Started Apr 2020; status: active.
02
Drugs
lipustobart
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on CTR20200784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200784.